Loading clinical trials...
Loading clinical trials...
The study will evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12) following a course of DAA therapy delivered using a simplified schedule of safety and vi...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Kirby Institute
Collaborators
NCT06953479 · HEPATITIS C (HCV), Incarceration, and more
NCT04162938 · Hepatitis C
NCT03694691 · Liver Cirrhoses
NCT07122700 · Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, and more
NCT03135886 · HIV/AIDS, Hepatitis C, and more
The Kirby Institute, University of New South Wales Australia
Sydney, New South Wales
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions